Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Leaflet HAEMATE P 250UI lyophilisate and solvent for solution for injection / infusion
- Product code:
- W13379001
- Quantity:
- 1
- Indicated for:
- bleeding; coagulation disorders
- Route of administration:
- injectable / infusion
- Substance:
- coagulation factor VIII and von Willebrand factor (coagulation factor)
- ATC
- B02BD06 — Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
Precautions:
Additional monitoring
This medicine is subject to additional monitoring.
Refrigerated storage
Store in the refrigerator as instructed in the leaflet.
The combination of coagulation factor VIII and von Willebrand factor is used in the treatment of hemophilia A and von Willebrand disease, two conditions involving blood clotting disorders. Factor VIII helps form the clot, while von Willebrand factor stabilizes factor VIII and facilitates platelet adhesion at the site of injury.
This combination is administered intravenously under medical supervision, with the dose adjusted according to the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, especially before surgeries or in case of trauma.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII and von Willebrand factor has significantly improved the quality of life for patients with bleeding disorders. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
This combination is administered intravenously under medical supervision, with the dose adjusted according to the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, especially before surgeries or in case of trauma.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII and von Willebrand factor has significantly improved the quality of life for patients with bleeding disorders. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
General data about HAEMATE P 250UI
- Substance:
- coagulation factor VIII and von Willebrand factor
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W13379001
- Pharmaceutical form:
- lyophilisate and solvent for solution for injection / infusion
- Packing volume:
- 250UI
- Product type:
- Generic medicine
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Pharmaceutical forms available for coagulation factor VIII and von Willebrand factor
Concentrations available for coagulation factor VIII and von Willebrand factor
- 1000UI
- 1000UI FVW/1000UI FVIII
- 1000UI/750UI
- 100UI/ml
- 250UI
- 250UI/190UI
- 450UI/400UI
- 500UI
- 500UI FVW/500UI FVIII
- 500UI+1200UI
- 500UI/375UI
- 900UI/800UI